Purpose: To report the successful use of tofacitinib in the treatment of refractory ocular mucous membrane pemphigoid (MMP). Observations: Two patients with ocular MMP presented with refractory disease after failure of multiple therapies. Treatment with tofacitinib led to durable control of conjunctival inflammation within 8 weeks and no apparent progression of sub-conjunctival fibrosis. One patient maintained absence of apparent disease activity over 16 months of follow-up. Cessation of tofacitinib in the other patient led to disease relapse which was reversed by re-initiation of therapy. Conclusions and importance: Small molecule inhibitors of Janus kinases, such as tofacitinib, may offer an effective treatment option for refractory ocular MMP.

Original languageEnglish
Article number101104
JournalAmerican Journal of Ophthalmology Case Reports
StatePublished - Jun 2021


  • JAK
  • JAK inhibitor
  • Mucous membrane pemphigoid
  • Ocular cicatricial pemphigoid
  • STAT
  • Tofacitinib


Dive into the research topics of 'Tofacitinib for refractory ocular mucous membrane pemphigoid'. Together they form a unique fingerprint.

Cite this